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Paclitaxel is an anti-microtubular agent with a known efficacy in
numerous adult solid tumours (Rowinsky and Donehower, 1995).
A phase I trial of paclitaxel in children with refractory solid
tumours showed that the recommended dose for phase II trials 
was 350 mg/m2 day–1 when administered as a 24-hour infusion.
The main dose-limiting toxicity was neurological (peripheral
neuropathy in one patient, tonic-clonic seizure in another). The
other toxicities encountered were expected from adult experience:
haematological toxicity, hypersensitivity (Hurwitz et al, 1993).
However, some clinical data support the fact that a 3-hour short-
term infusion of paclitaxel might offer equivalent anti-tumour effi-
cacy and reduced haematological toxicity without increasing the
risk of hypersensitivity (Eisenhauer et al, 1994). Phase I trials in
adults of paclitaxel administered as a 3-hour infusion showed that
the recommended dose for solid tumours was 210 mg/m2 or 250
mg/m2 with G-CSF support (Schiller et al, 1994; Younes et al,
1995). 
Despite the usual remarkable chemosensitivity of malignant
solid tumours in children, the development of new agents or new
methods of drug administration with demonstrated efficacy and
acceptable toxicity is still justified for refractory or relapsed
tumours. The aim of this study was to determine the dose-limiting
toxicity, maximum tolerated dose and pharmacokinetics of pacli-
taxel in children when administered as a 3-hour infusion. Since
paclitaxel has low water solubility, it is formulated for clinical use
in 50% cremophor EL and 50% ethanol, so that patients receiving
paclitaxel therapy also receive a significant amount of these
solvents. Because of the toxicity encountered, we also investigated
the pharmacokinetics of these two solvents. 
PATIENTS AND METHODS 
Eligibility 
Patients older than 6 months and younger than 20 years at the time
of treatment with histologically documented malignant solid
tumours, refractory to at least two lines of conventional thera-
peutic modalities with a life expectancy of more than 8 weeks
were eligible for the study, provided they satisfied the following
eligibility criteria: Lansky score ³50 (Lansky et al, 1987),
adequate haematological status (Granulocytes ³1000 ml–1,
platelets ³100 000 ml–1 except in the case of bone marrow involve-
ment), normal liver function (bilirubin ≤1.25  ´  N, AST and
ALT  ≤ 2 ´ N, fibrinogen ≤ 1 . 5gl –1 and prothrombin level ³60%),
adequate renal function (creatinine < 100 mmol l–1, creatinine
clearance ³70 ml min–1/1.73 m2), normal electrocardiogram and
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Summary The maximum tolerated dose of paclitaxel administered by 24-hour continuous infusion in children is known. Short infusion might
offer equivalent antitumour efficacy and reduced haematological toxicity, without increasing the allergic risk. Our aims were to determine the
maximum tolerated dose and the pharmacokinetics of paclitaxel in children when administered in 3-h infusion every 3 weeks. Patients older
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haematological toxicity was observed. Severe acute neurological and allergic toxicity was encountered. One treatment-related death occurred
just after the infusion at the highest dosage. Delayed peripheral neurotoxicity and moderate allergic reactions were also encountered.
Pharmacokinetic analysis showed dose-dependent clearance of paclitaxel and elevated blood ethanol and Cremophor EL levels. Although no
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echocardiography and no organ toxicity with WHO grade >2. In
patients with epilepsy, the plasma level of the antiepileptic drug had
to be within the therapeutic range. No other anticancer treatment
was allowed during the study and the time interval between previous
treatments and administration of paclitaxel had to be at least 3 weeks
and 6 weeks in the case of previous use of nitrosoureas. 
A patient could not be included in the case of severe infection,
previous large field irradiation (such as craniospinal irradiation),
previous use of high-dose chemotherapy with haematopoietic stem
cell transplantation, known heart disease, previous neurological
toxicity grade ³2, disseminated hepatic metastases and known
allergy to cremophor (e.g. previous allergy to teniposide). The
protocol was approved by ethical committee and by participating
institutions. Written informed consent was obtained from parents,
guardians and children when appropriate. 
Treatment 
Paclitaxel was supplied by Bristol Myers Squibb (Paris La
Défense, France) as a concentrated sterile solution in 50% poly-
oxy-ethylated castor oil (cremophor EL) and 50% dehydrated
ethanol. Paclitaxel was diluted to a final concentration of 0.3 to
1.2 mg ml–1 in 5% dextrose in water before administration over
3 hours with cardiac monitoring. Premedication was performed
using dexamethasone (0.25 mg kg–1, 12 and 6 hours before infu-
sion) and dexchlorpheniramine (2.5 to 5 mg according to age)
30 minutes before infusion. No H2-blocking agent was used. The
starting dose of paclitaxel was 240 mg/m2 taking into account the
recommended dose in adults for short-term infusion (Schiller et al,
1994) as well as the recommended dose in children for 24 hours
infusion (Hurwitz et al, 1993). Dose escalation was planned with
20% increments: second step 290 mg/m2, third step 350 mg/m2,
and fourth step 420 mg/m2. A minimum of 3 patients was included
at each step. There was no intra-patient dose escalation. 
Toxicity 
Toxicity criteria were assessed after the first course, according 
to NCl-CTC and WHO definitions respectively. Toxicity was
assessed after each course but dose-limiting toxicity was only
assessed after the first course. The dose-limiting toxicity criteria
were: persistence of grade IV neutropenia or thrombocytopenia for
more than 7 days, any grade IV non-haematological toxicity, any
grade III neurotoxicity, any grade III non-haematological toxicity
except grade III nausea, grade III transitory hepatotoxicity, grade
III fever and grade III mucositis. If at least two or more patients at a
given dose level encountered one of these criteria, the dose-limiting
toxicity (DLT) was reached and 3 additional patients were included
to be treated at the dose level preceding the DLT. 
Clinical examination, full blood count, liver, renal and elec-
trolyte values, chest X-ray and antiepileptic drug assay, when
applicable, were performed before each course. Haematological
toxicity was assessed by at least 3 full blood counts per week.
Except in the case of clinical evidence of disease progression after
one course, tumour evaluation was planned to be performed every
two courses. Patients could receive additional courses at 3-week
intervals except in the case of disease progression or stable disease
after 2 consecutive courses or dose-limiting toxicity. The eligib-
ility criteria for further courses were the same as for the first
course. The planned interval between two courses was 21 days
with a maximum interval of 35 days. 
Pharmacokinetic studies 
Blood samples were drawn before treatment and at 12 time points
during and for up to 72 hours after infusion (90 and 180 minutes
after the beginning of infusion; 10, 30, 60 minutes and 2, 4, 6, 12,
24, 48 and 72 hours after the end of infusion). Plasma was
obtained by centrifugation and frozen at -20˚C; 50ml to 1 ml of
patient plasma were assayed for total paclitaxel determination
by a validated high-performance liquid chromatography method
(Martin et al, 1998). The limit of quantification was 25 ng ml–1
(29 nM). In plasma spiked with 44, 440 and 750 ng ml–1, the
interassay variability was 11.18%, 2.97% and 3.02%, respectively.
Total area under the curve (AUC) was determined by the linear
trapezoidal rule extrapolated to infinity. The terminal rate constant
(b) was determined by log-linear least-squares fit of the terminal
elimination phase. Total-body clearance was calculated by
dividing the dose by AUC. The Cmax sample was drawn at the end
of infusion. Duration of threshold above 0.1 mM, which has been
reported to be correlated with more severe neutropenia (Huizing et
al, 1993; Gianni et al, 1995), has been determined in each patient.
Plasma alcohol was assayed by a standard gas liquid chromatog-
raphy method, using ethylacetate as internal standard. Cremophor
EL levels were quantified by an HPLC method based on saponifi-
cation of Cremophor EL, followed by extraction with chloroform
and derivatization of the released fatty acid ricinoleic acid as
described in detail previously (Sparreboom et al, 1996a) with
minor modifications (Van Tellingen et al, 1999). 
Correlation between observed toxicity and pharmacokinetic
parameters of paclitaxel and solvents were studied. 
Tumour response 
Response evaluation was planned after 2 courses and tumour
response was defined as follows: complete response, complete
regression of all apparent tumour masses; partial response, >50%
decrease in the product of the greatest perpendicular diameters of
all measurable lesions without appearance of new lesions; and
minimal response, >25% but less than 50% objective decrease in
measurable tumour without other evidence of disease progression.
Stable disease was defined as a less than 25% objective decrease
in a measurable tumour without other evidence of disease progres-
sion. Progressive disease was defined as a more than 25% increase
in any measurable tumour. Evaluation of tumour was not planned
after one course but a second course was not administered in the
case of obvious clinical progression or severe toxicity of the first
course. 
RESULTS 
Patient population 
Between February 1995 and November 1995, 17 patients were
included in the study and 4 dosage levels were investigated (Tables
1 and 2). 14 patients received only one course because of tumour
progression or toxicity and 3 patients received 2 courses. No
patients received more than 2 courses. The patient population
consisted of 6 females and 11 males with a median age of 9 years
(range: 19 months–19 years). Diagnoses are described in Table 1. 
11 patients were treated for primary refractory disease and 6
patients for relapse. One to 4 chemotherapy lines were used before
treatment with paclitaxel (median = 3) (Table 1). 8 patients had
also received previous localized radiotherapy. At the time of606 F Doz et al 
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treatment, Lansky score was 100 for 12 patients, between 60 and
80 for 5 patients with correct general status but reduced mobility
due to the tumour and 50 for one patient because of paraplegia.
Only one patient received an anti-epileptic drug (carbamazepine)
with a blood concentration within therapeutic range before treat-
ment. 
Acute toxicity (Table 2) 
We observed non-haematological dose-limiting toxicity in 2
patients after the first course at 420 mg/m2 and another grade IV
non-haematological toxicity in one patient after the second course
at 350 mg/m2. The first dose-limiting toxicity was observed in a
patient who was included in the study for a refractory metastatic
adrenocortical carcinoma treated with mitotane and hormonal
substitution; her Lansky score was 100. She presented with nausea
and headache 2 hours after starting the infusion followed by
vomiting and diarrhoea during the third hour of infusion. No rash
or oedema was observed. 30 minutes after the end of the infusion,
she developed haemodynamic failure with brief cardiac arrest. She
was rapidly managed with fluid modified gelatine, adrenaline
and hydrocortisone hemisuccinate. Routine laboratory tests were
performed while starting resuscitation and showed profound meta-
bolic acidosis and no hypoglycaemia. Despite active management
in the intensive care unit, she died as a result of multiorgan failure
syndrome 12 hours after the start of paclitaxel infusion. 
The other patient with dose-limiting toxicity had been included
for a refractory malignant glioma and had a Lansky score of 100
before treatment. He developed transitory coma few minutes after
the end of the infusion at 420 mg/m2; there was no abnormal
movement and the patient progressively recovered a normal level
of consciousness within 4 hours. During the study, another patient
experienced a similar neurological toxicity, but only after the
second course. This patient, included at the 350 mg/m2 level, was
19 months old and weighed 9.8 kg. Because of his young age and
low weight, and because of the previous toxicity observed at the
420 mg/m2 step, he received the first course at 2/3 of the theor-
etical dose (equivalent to 250 mg/m2) and had not experienced any
limiting toxicity. This patient then received a second course at the
full dose level and we observed transitory coma following this
second paclitaxel infusion. In both patients with transient coma,
routine laboratory tests were performed. No hypoglycaemia was
observed but transitory metabolic acidosis was found in both cases
(pH 7.26 and 7.23; bicarbonate 16 and 8 mmol l–1 respectively);
transient elevation of transaminases (5 ´ N) for 4 days in one of
these 2 patients was also noted. Electro-encephalogram was
performed in these 2 cases and showed no specific abnormality. 
One grade I central nervous system toxicity was also observed
with transitory alteration of consciousness in one patient receiving
concomitant morphine dose escalation. In two patients, transitory
grade I and II alteration of consciousness (anxiety or hypersomnia)
Table 1 Patients characteristics 
Characteristics No of patients 
Age, years 
Median 9 
Range 1.6–19 
Sex 
Male 11 
Female 6 
Tumour histology 
Rhabdomyosarcoma 7 
Ewing’s sarcoma 2 
Neuroblastoma 2 
Osteosarcoma 1 
Hepatoblastoma 1 
Nephroblastoma 1 
Malignant glioma 1 
Adrenocortical carcinoma 1 
Kruckenberg tumour 1 
No of prior therapy regimens 
0–2 5 
3–4 12 
Radiotherapy 6 
Table 2 Neurological and allergic toxicity after paclitaxel infusion 
Patient
Neurological toxicity Allergic toxicity 
number Dosage (mg m–2) Acute Grade Delayed Grade Acute Grade Delayed Grade 
201 290 
202 290 paraesthesia I rash/pruritis I 
II 203 290 dysaesthesia III rash/pruritis I 
204 290 mild agitation I excitation I rash/pruritis I 
205 290
206 290
301 350 somnolenceb I 
IIIa 302 350 headache, ileus 
303 350 and paraesthesia II 
311 250a
IIIb 311 350 coma IV
312 350 somnolence/agitation II mild pruritis  I rash/pruritis II 
401 420 coma IV dysaesthesia III 
IV 402 420
403 420 coma/agitation IV anaphylactic 
collapse/death IV 
Toxicity was assessed according to the NCI-CTC definitions. aPatient no.  311, step IIIB was 19 months old and weighed 9.8 kg: he received the first course at
2/3 of the theoretical dose (equivalent to 250 mg/m2) and no limiting toxicity was observed. This patient then received a second course at the full dose level (line
in italics) and transitory coma was observed following this second paclitaxel infusion. bpatient no. 301: had morphine dose escalation just before paclitaxel infusion. 3-hour paclitaxel infusion in children 607
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were noted during the infusion. No neurological toxicity was
observed in the patient who received carbamazepine anticonvul-
sive therapy. Grade I or II nausea was observed in three courses at
290 and 350 mg/m2. 
Delayed toxicity (Table 2) 
The observed haematological toxicity was not dose limiting.
Grade IV neutropenia was observed twice at the 240 and 350 mg/
m2 dosage levels, with a duration less than 7 days, and grade III
neutropenia was observed 5 times (at 290 and 350 mg/m2). No
grade IV leukopenia occurred; grade III leukopenia occurred
5 times at 240, 290 and 350 mg/m2. No thrombocytopenia was
encountered. Red blood cell transfusions were necessary in
4 courses for 3 patients receiving 290, 350 and 420 mg/m2; 2 of
these patients had an intra-tumour bleeding. Only one patient
experienced documented infection with Enterobacter septicaemia
during grade IV neutropenia (stage 4 neuroblastoma). 2 patients
experienced transitory fever of unknown origin without
neutropenia at 350 mg/m2. 
Delayed hypersensitivity reactions with skin rash and pruritis
were observed 4 times at 290 and 350 mg/m2. These symptoms
persisted for 7 to 19 days. One case of pruritis was observed 24
hours after the end of the infusion, which then persisted for 19
days associated with skin rash (grade II). In one patient, at the 350
mg/m2 dose, these symptoms occurred very intensively between
days 10 and 15 after the infusion and required hospitalization and
treatment with antihistaminic drugs, corticosteroids, benzodi-
azepine and morphine. Another patient presented paraesthesia and
grade III pruritis, but without skin rash, between day 5 and day 15
after a 420 mg/m2 infusion, requiring hospitalization and was
successfully treated by clonazepam, sulpiride and corticosteroids:
we interpreted these symptoms as a peripheral nervous system
toxicity rather than an allergic reaction. 
No mucositis was observed. One patient experienced grade I
delayed vomiting at 290 mg/m2. One patient experienced trans-
itory grade II diarrhoea, two days after the infusion at 350 mg/m2.
One patient also experienced transitory ileus at 350 mg/m2, but
with concomitant increasing morphine dosage. No late renal or
electrolyte abnormality was observed. Elevated transaminases 3
weeks after the infusion were recorded 3 times at the 290, 350 and
420 mg/m2 dosage levels to values 2 to 13 times normal values.
Alopecia was observed 3 times in 3 evaluable patients. 
Pharmacokinetics and correlation with toxicity 
Pharmacokinetic data were available for all 17 patients. The phar-
macokinetic analysis of the 19-month-old patient who was
included at the 350 mg/m2 dose level but treated during the first
course at 2/3 of the theoretical dose (equivalent to 250 mg/m2 for a
weight of 9.8 kg) was performed only during this first course: no
pharmacokinetic analysis was performed during the second course
at the full dose level associated with grade IV neurological 
toxicity. Selected pharmacokinetic parameters of paclitaxel are
listed in Table 3 together with the Cmax values for ethanol and
cremophor. Figure 1 illustrates the typical pharmacokinetic
profiles of paclitaxel at 290 mg/m2. For each dose level, mean
duration of paclitaxel plasma concentration threshold above 
0.1  mM was respectively 21, 24, 30 and 34 hours. In our study, we
observed high plasma alcohol levels after paclitaxel infusion: Cmax
values of ethanol ranged between 0.24 and 2.04 g l–1 (Table 3).
Furthermore, the Cmax concentrations of cremophor in plasma after
paclitaxel infusions ranged between 6.12 and 22.37 g l–1 (Table 3).
We retrospectively calculated that the amount of ethanol received
by the patients over 3 hours ranged between 0.39 and 1.05 g kg–1
and the amount of cremophor ranged between 0.52 and 1.4 g kg–1.
Severe neurological toxicity was observed in both patients with
the highest concentrations of ethanol and cremophor. 3 patients
with coma and somnolence in whom ethanol concentration was
measured have 3 of the 4 highest ethanol concentrations, above
1.45 g l–1. No clear correlation of the toxicity with age was
observed. 
Table 3 Pharmacokinetics of paclitaxel in children after 3-hour infusion. Determination of Cmax of the solvents, ethanol and cremophor. Means and standard deviation.
Paclitaxel data Alcool Cremophor 
Dose level Cmax Clexp AUCexp T1/2elim Vb Cmax Cmax
mg/m2 mM L/h/m2 mMxh H L (g l–1)( g l –1b) 
240 8.3a 8.48 33.8 7.23 140.8 0.40a 8.37a
(2.1) (1.24) (4.8) (1.34) (31.1) (0.15) (2.05) 
290 22.4 4.99 70.8 9.69 71.7 0.93 13.15 
(6.5) (0.99) (15.7) (4.93) (38.6) (0.24) (2.29) 
350 40.2 3.39 156.7 5.23 19.2 1.17 16.9 
(17.8) (1.61) (75.7) (1.36) (9.1) (0.39) (3.4) 
420 38.9a 2.74 179.6 10.24 39.4 1.6a 18.9a
(4.9) (0.01) (0.1) (0.8) (8.3) (0.38) (3.6) 
aCmax under-estimated in 2 cases because infusion duration greater than 3 hours. b1gl –1 = 0.95 mlm l –1
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Figure 1 Plasma concentrations of paclitaxel in children treated with
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Tumour responses 
Tumour response was evaluable in all patients, except for one case
because of early death. One patient treated for embryonal rhab-
domyosarcoma experienced a more than 50% decrease of an
abdominal lymph node after one course at 350 mg/m2, but treat-
ment had to be stopped because of a delayed allergic reaction.
Stable disease was observed after 2 courses at 350 mg/m2 in one
patient with alveolar rhabdomyosarcoma but the treatment had to
be stopped because of a severe toxicity at the second course. For
2 other patients, we did not observe disease progression after one
course but treatment had to be stopped because of severe toxicity.
Disease progression was observed in the 12 other evaluable
patients (10 after 1 course, 2 after 2 courses). 
DISCUSSION 
The haematological toxicity was not dose limiting in this study,
despite high paclitaxel Cmax and prolonged time of paclitaxel
plasma levels above 0.1 mM which is usually correlated to more
severe neutropenia (Huizing et al, 1993; Gianni et al, 1995). This
low haematological toxicity, associated with apparent high drug
exposure, might be due to a better haematological tolerance of
paclitaxel in children than in adults. However, this might also be
due to interference between the paclitaxel and cremophor EL phar-
macokinetics: it has been recently reported that the higher plasma
levels of paclitaxel do not reflect higher levels in tissues, since
cremophor EL increases the affinity of paclitaxel to plasma
components (Van Tellingen et al, 1999). 
On the other hand, acute non-haematological toxicity was dose
limiting and related to high Cmax of paclitaxel, ethanol and
cremophor EL. Severe acute toxicity were observed in 2 patients
after the first course given at a dose of 420 mg/m2 and also in an
infant who received the full dose of 350 mg/m2 for the second
course. The origin of the toxic death observed at the fourth dosage
level is difficult to determine: the initial symptoms and clinical
history are concordant with severe allergic reaction and/or acute
neurological toxicity, occurring in a debilitated patient dependent
on hydrocortisone replacement therapy. Similar toxicity was not
observed when the same dosages were given to children over 24
hours. However, the central nervous system toxicity of paclitaxel
has already been reported: seizures in children (Hurwitz et al,
1993), alteration of consciousness (Webster et al, 1996; Chang 
et al, 1998; Glück et al, 1998) or neurovegetative disorders
(Vassilomanolakis et al, 1998) in adults. The mechanism of acute
neurological toxicity is not completely understood. The well
known peripheral nervous system toxicity (Hurwitz et al, 1993;
Cavaletti et al, 1995; Seidman et al, 1995; Glantz et al, 1996), also
observed in our study, might reflect a direct axonal toxicity, that
may also affect the central nervous system. However, brain pene-
tration of paclitaxel is known to be limited (Eiseman et al, 1994;
Glantz et al, 1995). Nevertheless, grade IV neurological toxicity
was encountered for the highest plasma concentrations and AUC
of paclitaxel and the lowest clearances. The role of ethanol, used
as paclitaxel solvent, must also be stressed in the acute neurolo-
gical toxicity. Ethanol causes cardiovascular and central nervous
system toxicity, direct vasodilatation (Litovitz, 1986) and hypogly-
caemia as well as metabolic acidosis (Ellenhorn, 1997). In our
study, transitory metabolic acidosis but no hypoglycaemia was
observed in both patients who experienced transitory coma at 
the end of the infusion; in one patient, a transitory increase of
transaminases was observed (5 ´ N) but with no other hepatic
abnormality. Ethanol is used as a solvent for other cytotoxic drugs
such as etoposide or BCNU. The quantity of ethanol delivered
with etoposide in a CARBOPEC regimen (Namouni et al, 1997) is
0.14 g kg–1 day–1 in 1 hour from D1 to D5. The quantity of ethanol
delivered with BCNU in a BEAM regimen (Gaspard et al, 1988) is
0 . 3gk g –1 in 1 hour. At 420 mg/m2 dose level, the quantity of
ethanol delivered with paclitaxel in this study was 1.05 g kg–1 in 3
hours. Lethal doses of ethanol in children are known to be around
3gk g –1 but this is mainly reported after oral intoxication. Blood
concentrations above 3 g l–1 are known to be potentially lethal.
Ethanol assays in plasma samples collected for pharmacokinetic
analysis showed elevated blood ethanol levels compatible with
acute reversible neurological toxicity, but not necessarily
explaining the toxic death (Moss, 1970; Sellers and Kalant, 1976;
Landers, 1983; Adinoff et al, 1988). Somnolence and coma may be
correlated partly with ethanol exposure (high Cmax and duration of
plasma alcohol concentrations above 0.5 g l–1). Ethanol assays
have also been reported in adults treated with paclitaxel. In one
report (Webster et al, 1996), ethanol Cmax after 175 mg/m2 of pacli-
taxel did not exceed 0.09 g l–1 in 10 out of 12 patients, but reached
values of 0.17 and 0.33 g l–1 in 2 other patients. Wilson (Wilson et
al, 1997) reported a case of ethanol intoxication associated with a
3-hour dose of 350 mg/m2 paclitaxel infusion, leading to an
ethanol concentration of 0.98 g l–1. Finally, the role of cremophor
in acute neurological toxicity must also be discussed, as
cremophor has been shown in vitro to induce demyelinization and
axonal swelling and degeneration (Windenbank et al, 1994) at
levels that are largely achieved in vivo using 3-hour paclitaxel
infusions. In any case, in view of the acute neurological toxicity
and elevated plasma alcohol concentrations which had not been
anticipated and were not associated with any dose-limiting haema-
tological toxicity, we considered that this paclitaxel schedule was
definitely not recommended in children. Indeed, because of the
suspected role of solvents in this non-haematological severe toxi-
city, the study was closed without including the 2 more patients at
the third dose level. 
The other main toxicity encountered in this study was allergic.
Allergy to paclitaxel is usually thought to be due to cremophor and
is generally successfully prevented by anti-allergic premedication.
Cremophor has been implicated as a probable cause of anaphylac-
toid reactions following administration of cremophor-containing
drugs, such as cyclosporin or teniposide (Chapuis et al, 1985;
Magalini et al, 1986; MacLeod et al, 1991; Theis et al, 1995; Nolte
et al, 1998). Such a severe allergic reaction might also be involved
in the origin of the toxic death that occurred in our study. However,
given the allergic toxicity described with the analogue docetaxel
(Seibel et al, 1999), which is delivered without cremophor EL,
paclitaxel itself might also be involved in these allergic reactions.
The use of an H2-blocking agent has been recommended before
paclitaxel infusion in adults (Schiller et al, 1994), but remains
controversial and was not used in the previous phase I trial in
children (Hurwitz et al, 1993). 
The pharmacokinetics of paclitaxel in 3 hour infusion showed
specific characteristics. Clearance of paclitaxel appeared to
decrease as the dosage increased from 240 to 420 mg/m2 and the
maximum concentration and area under the curve increased more
than in proportion to the dose. As in adults (Eisenhauer et al, 1994;
Sonnichsen et al, 1994a; Gianni et al, 1995; Kearns et al 1995),
these results suggest that paclitaxel pharmacokinetics is non-linear
when the drug is administered as a 3-hour infusion in children.Mean paclitaxel clearances in children (8.48 to 2.74 l h–1/m2) were
within the range reported for adults after short-term administration
(Sonnichsen et al, 1994a; Gianni et al, 1995; Kearns et al, 1995)
but clearances tended to be lower after the 3-hour infusion (our
study) compared to the 24-hour infusion value in children
(Sonnichsen et al, 1994b). However, although it has previously
been proposed that paclitaxel’s nonlinear pharmacokinetic beha-
viour is due to saturable distribution and elimination processes,
recent reports strongly suggest that this non-linear behaviour
results from entrapment of paclitaxel in cremophor EL micelles in
plasma (Sparreboom et al, 1996b, 1999; Van Tellingen et al, 1999).
This effect makes it difficult to use the clearance as parameter for
drug exposure, as the actual exposure to ‘free’ paclitaxel depends
on the plasma level of cremophor EL. The pharmacokinetics of
cremophor EL itself was only studied in adults (Rischin et al,
1996; Sparreboom et al, 1999; Van Tellingen et al, 1999). These
studies have shown that the Cmax of cremophor EL increases
linearly with the dose administered. At the highest dose level
tested in adults (Sparreboom et al, 1999) of 225 mg/m2, the Cmax of
cremophor EL was 6.58 ± 0.52 ml ml–1 (i.e. 6.94  0.55 mg ml–1),
which is comparable to the levels found in our study in children
receiving the lowest dose of 240 mg/m2. Further increments in 
the dose given to children resulted in a linear increase in the
cremophor EL Cmax levels. Consequently, the Cmax level of cremo-
phor EL at the highest dose (420 mg/m2) is more than 2-fold
higher than in adults receiving conventional doses of paclitaxel,
which might explain the apparent non-linearity of paclitaxel’s
clearance and the low haematological toxicity. 
Regarding anti-tumour activity, the only tumour response in this
study was obtained in one patient treated for recurrent rhab-
domyosarcoma. It might be interesting to investigate other pacli-
taxel schedules in this diagnosis (Hurwitz et al, 1993). 
In conclusion, dose-limiting toxicity of this modality of pacli-
taxel administration in children, is neurological and, possibly,
allergic. The combination of paclitaxel, ethanol and cremophor EL
is responsible for neurotoxicity; since all components may play a
role, it does not seem appropriate to relate toxicity to specifically
one component. Paclitaxel administration as a 3-hour infusion
every 3 weeks is definitely not recommended in children. Short-
term infusions may be used for administration at lower doses, such
as weekly (Glantz et al, 1996) or fractionated daily doses (Don
Francesco et al, 1996). In addition, plasma alcohol levels should
be monitored in children receiving paclitaxel at any dose level. 
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